% will be given today @ agm, page-10

This from their release to ASX 31st Oct :-

So we know the royalty is less than 10%




Q. What are the key financial terms of the sub-license with Merial?

A. For competitive advantage reasons the key financial terms of the sub-
license must remain confidential. Imugene will receive sign up fees
followed by milestone payments in the product development process and
royalty payments on product sales following successful
commercialisation. The agreement also includes agreed minimum
performance requirements and timelines. The license grants Merial the
right to use the Fowl Adenovirus Delivery Vector only for this poultry
product and Imugene retains the rights to develop other products from
this platform technology. In animal health product licensing
arrangements, it is usual to see single digit royalty rates.